Two-year outcomes of intravitreal ziv-aflibercept
British Journal of Ophthalmology Jan 13, 2018
Mansour AM, et al. - As a part of this trial, researchers inspected the two-year outcome of intravitreal ziv-aflibercept (IVZ) in eyes with macular diseases. They concluded that IVZ was safe and efficacious in the treatment of macular diseases through 2 years.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
